 |
Top 13 Startups developing Cancer Vaccines
Oct 11, 2024 | By Jason Kwon | 15 |
These startups develop personalized cancer vaccines that aim to prevent or treat cancer by stimulating the body's targeted immune response against cancer cells.
1
Country: USA | Funding: $253.8M
Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer.
Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer.
2
Country: Germany | Funding: $1.9B
We are developing the next generation of personalized immunotherapies to help revolutionize the treatment of people with cancer and other debilitating diseases.
We are developing the next generation of personalized immunotherapies to help revolutionize the treatment of people with cancer and other debilitating diseases.
3
Country: Denmark | Funding: $175M
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines.
4
Country: Australia | Funding: A$80M
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
5
Country: USA | Funding: $78.4M
Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines.
Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines.
6
Country: USA | Funding: $34.3M
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
7
Country: Norway | Funding: NOK270M
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer.
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer.
8
Country: South Korea | Funding: ₩27B
Aston Sci is a clinical-stage biopharmaceutical company that develops medicines in oncology, immunology, and geriatrics. It's cancer vaccine is being evaluated for breast and gastric cancer
Aston Sci is a clinical-stage biopharmaceutical company that develops medicines in oncology, immunology, and geriatrics. It's cancer vaccine is being evaluated for breast and gastric cancer
9
Country: UK | Funding: £15.7M
Scancell is focused on developing innovative immunotherapies for cancer that stimulate the body’s own immune system.
Scancell is focused on developing innovative immunotherapies for cancer that stimulate the body’s own immune system.
10
Country: USA | Funding: $9.9M
BioVaxys is a clinical stage biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma and ovarian cancer.
BioVaxys is a clinical stage biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma and ovarian cancer.
